Week-12 Response to Therapy as a Predictor of Week 24, 48, and 96 Outcome in Patients Receiving the HIV Fusion Inhibitor Enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) Trials
Open Access
- 15 March 2006
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 42 (6) , 870-877
- https://doi.org/10.1086/500206
Abstract
Background. Early virological response to antiretroviral therapy is predictive of long-term treatment outcome in therapy-naive patients. In treatmentKeywords
This publication has 12 references indexed in Scilit:
- Peptide inhibitors of virus—cell fusion: enfuvirtide as a case study in clinical discovery and developmentThe Lancet Infectious Diseases, 2004
- Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtideAIDS, 2004
- Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and AustraliaNew England Journal of Medicine, 2003
- Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South AmericaNew England Journal of Medicine, 2003
- Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacyThe Lancet, 2001
- Patterns of Plasma Human Immunodeficiency Virus Type 1 RNA Response to Antiretroviral TherapyThe Journal of Infectious Diseases, 2001
- Short-Term Measures of Relative Efficacy Predict Longer-Term Reductions in Human Immunodeficiency Virus Type 1 RNA Levels following Nelfinavir MonotherapyAntimicrobial Agents and Chemotherapy, 2001
- The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4–8 viral loadAIDS, 2001
- Predictors of optimal virological response to potent antiretroviral therapyAIDS, 1999
- A survey of drug-resistant Mycobacterium tuberculosis and its relationship to HIV infectionAIDS, 1998